JPH11349565A - Production of pyridonecarboxylic acid derivative and intermediate thereof - Google Patents

Production of pyridonecarboxylic acid derivative and intermediate thereof

Info

Publication number
JPH11349565A
JPH11349565A JP10173986A JP17398698A JPH11349565A JP H11349565 A JPH11349565 A JP H11349565A JP 10173986 A JP10173986 A JP 10173986A JP 17398698 A JP17398698 A JP 17398698A JP H11349565 A JPH11349565 A JP H11349565A
Authority
JP
Japan
Prior art keywords
tert
butoxycarbonyl
hydroxypyrrolidine
following formula
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP10173986A
Other languages
Japanese (ja)
Other versions
JP4294121B2 (en
Inventor
Yasutomo Chikugi
保知 筑木
Kazuhiro Mizuno
和弘 水野
Katsumi Chiba
勝已 千葉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dainippon Pharmaceutical Co Ltd
Original Assignee
Dainippon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co Ltd filed Critical Dainippon Pharmaceutical Co Ltd
Priority to JP17398698A priority Critical patent/JP4294121B2/en
Publication of JPH11349565A publication Critical patent/JPH11349565A/en
Application granted granted Critical
Publication of JP4294121B2 publication Critical patent/JP4294121B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PROBLEM TO BE SOLVED: To obtain a new compound useful as an intermediate for producing pyridonecarboxylic acid derivatives. SOLUTION: This new compound, 1-t-butoxycarbonyl-trans-3-benzylamino-4- hydroxypyrrolidine, is shown by formula I (Boc is t-butoxycarbonyl; Ph is phenyl), being obtained, for example, by the following procedure: t-butyl carbamate is reacted with cis-1,4-dichloro-2-butene in the presence of sodium hydride to form 1-t-butoxycarbonyl-3-pyrroline, which is then reacted with N- bromosuccinimide to form a compound of formula II, which, in turn, reacted with a base and benzylamine. The other objective pyridonecarboxylic acid derivative of formula III is obtained by the following procedure: the compound of formula I is subjected to optical resolution using (+)-mandelic acid and then treated with a base followed by ciebenzylation and Boc group introduction, methylation, and then elimination of the Boc group to form a compound of formula IV, which is then reacted with a compound of formula V L is an eliminable group; R is H or the like) followed by hydrolysis or the like.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、下記構造を有する
ピリドンカルボン酸誘導体(以下、最終目的化合物また
は化合物(C)ということもある)を製造するための中
間体、その中間体自体の製造方法およびその中間体から
最終目的化合物またはその生理的に許容される塩を製造
する方法に関するものである。
TECHNICAL FIELD The present invention relates to an intermediate for producing a pyridonecarboxylic acid derivative having the following structure (hereinafter sometimes referred to as the final target compound or compound (C)), and a method for producing the intermediate itself. And a method for producing a final target compound or a physiologically acceptable salt thereof from an intermediate thereof.

【0002】[0002]

【化12】 Embedded image

【0003】[0003]

【従来の技術と発明が解決しようとする課題】特開平9
−221424号公報には、前記〔化12〕で表される
ピリドンカルボン酸誘導体〔化合物(C)〕が抗ガン剤
として極めて優れていることが記載されている。この化
合物(C)は、7−クロロ−1,4−ジヒドロ−4−オ
キソ−1−(2−チアゾリル)−1,8−ナフチリジン
−3−カルボン酸エチルエステルと(+)−トランス−
3−tert−ブトキシカルボニルアミノ−4−メトキシピ
ロリジン(B’)とを反応させることにより製造され、
ここにおける後者の原料(B’)は、次の〔化13〕に
示される反応式に従って製造されることが、同公開公報
の実施例B−2に記載されている。
BACKGROUND OF THE INVENTION Problems to be Solved by the Invention
JP-A-220424 describes that the pyridonecarboxylic acid derivative [compound (C)] represented by the above [Chemical Formula 12] is extremely excellent as an anticancer agent. This compound (C) is obtained by converting 7-chloro-1,4-dihydro-4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid ethyl ester with (+)-trans-
Produced by reacting 3-tert-butoxycarbonylamino-4-methoxypyrrolidine (B ′);
It is described in Example B-2 of the publication that the latter raw material (B ') is produced according to the following reaction formula shown in [Formula 13].

【0004】なお、本明細書において、「Boc」とあ
るのはtert−ブトキシカルボニル基を意味し、「Ph」
とあるのはフェニル基を意味する。
[0004] In the present specification, "Boc" means a tert-butoxycarbonyl group, and "Ph"
“A” means a phenyl group.

【0005】[0005]

【化13】 Embedded image

【0006】しかし、前記反応式〔化13〕で表される
従来法は、工業的製法としては、必ずしも満足できる方
法ではない。例えば、全体としてN−メチル化とO−メ
チル化とを別個に行っている点において、更に従来法に
おける光学分割における収率(52%)がやや低いもので
ある点において、この従来法は工業的製法として満足な
ものではなかった。
However, the conventional method represented by the above-mentioned reaction formula [Formula 13] is not always satisfactory as an industrial production method. For example, the conventional method is industrial in that the N-methylation and the O-methylation are separately performed as a whole, and that the yield (52%) in the optical resolution in the conventional method is rather low. It was not satisfactory as a typical manufacturing method.

【0007】なお、光学分割における収率は、用いたラ
セミ体の半量の光学活性体が得られたときを100 %とし
て計算することにする。
[0007] The yield in the optical resolution is calculated assuming that half of the racemic form used is obtained as an optically active substance, as 100%.

【0008】また、前記の従来法における出発物質たる
化合物(A’)は、特開平2−69474号公報に記載
の方法、すなわち、次の〔化14〕で表される方法によ
って製造することができる。
The starting compound (A ') in the above-mentioned conventional method can be produced by the method described in JP-A-2-69474, that is, the method represented by the following chemical formula (14). it can.

【0009】[0009]

【化14】 Embedded image

【0010】前記、〔化14〕で示される中間体の製造
方法は、各生成物の精製にカラム精製法を使わざるを得
ない点において、そして、アジド基からアミノ基への変
換に取扱が容易でない水素化リチウムアルミニウムを使
用している点において、工業的製法としては採用しがた
いものであった。
The method for producing the intermediate represented by the above formula [Chemical Formula 14] is inevitable that a column purification method must be used for purifying each product, and the method for converting an azide group to an amino group is not applicable. The use of lithium aluminum hydride, which is not easy, has been difficult to employ as an industrial production method.

【0011】[0011]

【課題を解決するための手段】そこで本発明者らは、か
かる従来法における問題点の解決を目指して鋭意検討し
た結果、工業的製法として優れた本発明を完成した。
The inventors of the present invention have made intensive studies to solve the problems in the conventional method, and as a result, have completed the present invention which is excellent as an industrial production method.

【0012】本発明は、次式(A)The present invention provides the following formula (A)

【0013】[0013]

【化15】 Embedded image

【0014】で表される1−tert−ブトキシカルボニル
−トランス−3−ベンジルアミノ−4−ヒドロキシピロ
リジンまたはその酸付加塩に関するものである。
1-tert-butoxycarbonyl-trans-3-benzylamino-4-hydroxypyrrolidine or an acid addition salt thereof.

【0015】前記化合物(A)は、文献に具体的に記載
されたことがないと信じられる化合物であり、本発明方
法、すなわち、以下の製造方法(I)または(II) によ
り工業的にに製造することができる。
The compound (A) is a compound which is believed not to be specifically described in the literature, and can be industrially produced by the method of the present invention, ie, the following production method (I) or (II). Can be manufactured.

【0016】製造方法(I):中間体(A)の製造−−
製造方法(I)は以下の工程1−3から構成され、各工
程の反応条件などの詳細は後記実施例に記載されてい
る。
Production method (I): Production of intermediate (A)
The production method (I) comprises the following steps 1-3, and details such as reaction conditions of each step are described in Examples below.

【0017】〔工程1〕:本工程は閉環反応により3−
ピロリンを形成させる工程である。すなわち、本工程は
水素化ナトリウムの存在下、次式(1)
[Step 1]: This step is performed by a ring-closure reaction.
This is a step of forming pyrroline. That is, this step is performed in the presence of sodium hydride by the following formula (1)

【0018】[0018]

【化16】 Embedded image

【0019】で表されるシス−1,4−ジクロロ−2−
ブテンにtert−ブチルカルバメイトを反応させて1−te
rt−ブトキシカルボニル−3−ピロリンとなすことによ
り実施できる。本工程の収率は約50−60%である。
Cis-1,4-dichloro-2-represented by
Butene is reacted with tert-butyl carbamate to give 1-te
It can be carried out by using rt-butoxycarbonyl-3-pyrroline. The yield of this step is about 50-60%.

【0020】〔工程2}:本工程はブロム化とヒドロキ
シル化に関する工程である。すなわち、本工程は工程1
で得られた化合物にN−ブロモスクシンイミドを反応さ
せて次式(2)
[Step 2}: This step is a step relating to bromination and hydroxylation. That is, this step is Step 1.
Is reacted with N-bromosuccinimide to give the following formula (2)

【0021】[0021]

【化17】 Embedded image

【0022】で表される1−tert−ブトキシカルボニル
−トランス−3−ブロモ−4−ヒドロキシピロリジンと
なすことにより実施できる。得られる化合物(2)は、
通常、精製することなく次の工程の原料として使用され
る。
The reaction can be carried out by using 1-tert-butoxycarbonyl-trans-3-bromo-4-hydroxypyrrolidine represented by the formula: Compound (2) obtained is
Usually, it is used as a raw material in the next step without purification.

【0023】〔工程3〕:本工程はベンジルアミノ化に
関するものである。すなわち、本工程は工程2で得た化
合物に水酸化ナトリウムの如き塩基、次いでベンジルア
ミンを反応させて目的とする1−tert−ブトキシカルボ
ニル−トランス−3−ベンジルアミノ−4−ヒドロキシ
ピロリジン(A)となすことにより実施できる。前工程
2から本工程3までの収率は50%前後である。
[Step 3]: This step relates to benzyl amination. That is, in this step, the desired 1-tert-butoxycarbonyl-trans-3-benzylamino-4-hydroxypyrrolidine (A) is obtained by reacting the compound obtained in step 2 with a base such as sodium hydroxide and then with benzylamine. Can be implemented. The yield from the previous step 2 to the present step 3 is around 50%.

【0024】製造方法(II):中間体Aの製造−−製造
方法(II)は以下の工程4および5から構成され、各工
程の反応条件などの詳細は後記実施例に記載されてい
る。
Production Method (II): Production of Intermediate A --Production Method (II) comprises the following steps 4 and 5, and details such as reaction conditions of each step are described in Examples below.

【0025】〔工程4〕:本工程はBoc基の導入に関
する工程である。すなわち、本工程は次式(3)
[Step 4]: This step relates to the introduction of a Boc group. That is, this step is represented by the following equation (3)

【0026】[0026]

【化18】 Embedded image

【0027】で表される3−ピロリンの1位にBoc基
を導入して1−tert−ブトキシカルボニル−3−ピロリ
ンとなすことにより実施できる。Boc基の導入は、例
えば、二炭酸ジtert−ブチルを用いることにより行われ
る。
In this method, a Boc group is introduced at the 1-position of 3-pyrroline to form 1-tert-butoxycarbonyl-3-pyrroline. The Boc group is introduced by using, for example, ditert-butyl dicarbonate.

【0028】〔工程5〕:本工程は酸化とベンジルアミ
ノ化に関するものである。すなわち、本工程は工程4で
得られた化合物を酸化して次式(4)
[Step 5]: This step relates to oxidation and benzyl amination. That is, in this step, the compound obtained in step 4 is oxidized to give the following formula (4)

【0029】[0029]

【化19】 Embedded image

【0030】で表される化合物となし、これにベンジル
アミンを反応させて1−tert−ブトキシカルボニル−ト
ランス−3−ベンジルアミノ−4−ヒドロキシピロリジ
ン(A)となすことにより実施できる。酸化は、通常、
m−クロロ過安息香酸を用いて行われる。
The reaction can be carried out by reacting the compound with benzylamine to give 1-tert-butoxycarbonyl-trans-3-benzylamino-4-hydroxypyrrolidine (A). Oxidation is usually
The reaction is performed using m-chloroperbenzoic acid.

【0031】前記の工程4と5は、途中の生成物を精製
することなく連続して行うことができ、この場合の全収
率は約40%である。
Steps 4 and 5 above can be carried out continuously without purification of the intermediate product, in which case the overall yield is about 40%.

【0032】製造方法(III) :中間体Bの製造−−ま
た、本発明は、ピリドンカルボン酸の製造における直接
の中間体である(3S,4S)−3−メトキシ−4−メ
チルアミノピロリジン(B)またはその酸付加塩の製造
方法に関するものである。すなわち、本発明は以下の工
程6−9を順次行うことを特徴とする次式(B)
Production method (III): Production of intermediate B --The present invention also relates to (3S, 4S) -3-methoxy-4-methylaminopyrrolidine which is a direct intermediate in the production of pyridonecarboxylic acid. B) or a method for producing an acid addition salt thereof. That is, the present invention sequentially performs the following steps 6-9, wherein the following formula (B)

【0033】[0033]

【化20】 Embedded image

【0034】で表される(3S,4S)−3−メトキシ
−4−メチルアミノピロリジンまたはその酸付加塩の製
造方法を提供するものである。
It is intended to provide a method for producing (3S, 4S) -3-methoxy-4-methylaminopyrrolidine or an acid addition salt thereof represented by the formula:

【0035】〔工程6〕;本工程は光学分割に関するも
のであり、次式(A)
[Step 6]: This step relates to optical resolution, and the following formula (A)

【0036】[0036]

【化21】 Embedded image

【0037】で表される1−tert−ブトキシカルボニル
−トランス−3−ベンジルアミノ−4−ヒドロキシピロ
リジンを(+)−マンデル酸により光学分割を行った
後、塩基処理して遊離の(+)−1−tert−ブトキシカ
ルボニル−(3S,4S)−3−ベンジルアミノ−4−
ヒドロキシピロリジンとなすことにより実施できる。
After optically resolving 1-tert-butoxycarbonyl-trans-3-benzylamino-4-hydroxypyrrolidine represented by the following formula with (+)-mandelic acid, it is treated with a base to give free (+)- 1-tert-butoxycarbonyl- (3S, 4S) -3-benzylamino-4-
It can be carried out by using hydroxypyrrolidine.

【0038】本工程6では、化合物(A)とやや過剰量
の(+)−マンデル酸とをアセトニトリルおよび水から
なる混液などの溶媒に溶解し、数時間室温で放置し、析
出するマンデル酸塩を数回の再結晶により精製し、精製
したマンデル酸塩を炭酸カリウムの如き塩基で処理する
ことにより化合物(A)の光学活性体、すなわち、遊離
の(+)−1−tert−ブトキシカルボニル−(3S,4
S)−3−ベンジルアミノ−4−ヒドロキシピロリジン
を得ることができる。マンデル酸塩の再結晶は、通常、
アセトニトリルと水の混液(20:1、V/V )を用いて行
われる。本工程の収率は約70−80%である。
In this step 6, the compound (A) and a slightly excessive amount of (+)-mandelic acid are dissolved in a solvent such as a mixture of acetonitrile and water and left at room temperature for several hours to precipitate mandelic acid salt. Is purified by recrystallization several times, and the purified mandelic acid salt is treated with a base such as potassium carbonate to give an optically active form of compound (A), ie, free (+)-1-tert-butoxycarbonyl- (3S, 4
S) -3-Benzylamino-4-hydroxypyrrolidine can be obtained. The recrystallization of mandelate is usually
The reaction is performed using a mixture of acetonitrile and water (20: 1, V / V). The yield of this step is about 70-80%.

【0039】〔工程7〕:本工程はベンジル基の脱離と
Boc基の導入に関するものである。すなわち、本工程
は工程6で得た化合物を脱ベンジル化反応およびBoc
基導入反応に付して次式(5)
[Step 7]: This step relates to elimination of a benzyl group and introduction of a Boc group. That is, in this step, the compound obtained in Step 6 is subjected to a debenzylation reaction and Boc
Following the group introduction reaction, the following formula (5)

【0040】[0040]

【化22】 Embedded image

【0041】で表される(+)−1−tert−ブトキシカ
ルボニル−(3S,4S)−3−tert−ブトキシカルボ
ニルアミノ−4−ヒドロキシピロリジンとなすことによ
り実施できる。
(+)-1-tert-butoxycarbonyl- (3S, 4S) -3-tert-butoxycarbonylamino-4-hydroxypyrrolidine represented by the formula:

【0042】ここにおける脱ベンジル化反応は、例え
ば、パラジウム−炭素を触媒とする接触還元により実施
でき、Boc基の導入には二炭酸ジtert−ブチルが用い
られる。本工程は、ほぼ定量的に行える。
The debenzylation reaction here can be carried out, for example, by catalytic reduction using palladium-carbon as a catalyst, and ditert-butyl dicarbonate is used to introduce a Boc group. This step can be performed almost quantitatively.

【0043】〔工程8〕:本工程はメチル化に関するも
のである。すなわち、本工程は水素化ナトリウムの存在
下、工程7で得た化合物をメチル化して次式(6)
[Step 8]: This step relates to methylation. That is, in this step, in the presence of sodium hydride, the compound obtained in step 7 is methylated to give the following formula (6)

【0044】[0044]

【化23】 Embedded image

【0045】で表される(+)−1−tert−ブトキシカ
ルボニル−(3S,4S)−3−〔(N−tert−ブトキ
シカルボニル−N−メチル)アミノ〕−4−メトキシシ
ピロリジンとなすことにより実施できる。
(+)-1-tert-butoxycarbonyl- (3S, 4S) -3-[(N-tert-butoxycarbonyl-N-methyl) amino] -4-methoxycypyrrolidine Can be implemented.

【0046】さらに詳細には、本工程は水素化ナトリウ
ムを懸濁した無水ジメチルホルムアルデヒドにヨウ化メ
チルを加え、これに前工程で得た化合物を含む溶液をゆ
っくりと滴下することにより実施でき、N−メチル化と
O−メチル化が同時に、かつ、ほぼ定量的に行える。
More specifically, this step can be carried out by adding methyl iodide to anhydrous dimethylformaldehyde in which sodium hydride is suspended, and slowly adding dropwise a solution containing the compound obtained in the previous step to this. -Methylation and O-methylation can be performed simultaneously and almost quantitatively.

【0047】〔工程9〕:本工程はBoc基の脱離に関
するものである。すなわち、本工程は工程8で得られた
化合物のBoc基を脱離して目的化合物(B)となし、
次いで所望により、遊離塩基が得られたときは酸付加塩
に変換し、酸付加塩が得られたときは遊離塩基に変換す
ることにより実施できる。
[Step 9]: This step relates to elimination of the Boc group. That is, in this step, the Boc group of the compound obtained in Step 8 is eliminated to form the target compound (B),
Then, if desired, the reaction can be carried out by converting the free base to an acid addition salt when it is obtained, and converting the acid addition salt to a free base when the acid base is obtained.

【0048】本工程は、常法により実施できるが、前工
程で得られた化合物をp−トルエンスルホン酸で処理し
てBoc基を脱離すると同時に結晶性に優れた二p−ト
ルエンスルホン酸塩として目的物を得るのが好ましい。
本工程の収率は約90%以上である。
This step can be carried out by a conventional method. However, the compound obtained in the preceding step is treated with p-toluenesulfonic acid to remove the Boc group and, at the same time, to obtain a di-p-toluenesulfonic acid salt having excellent crystallinity. It is preferable to obtain the target product as
The yield of this step is about 90% or more.

【0049】製造方法(III) の総収率は、約55−65%で
ある。
The total yield of process (III) is about 55-65%.

【0050】製造方法(IV):最終目的物(C)の製造
−かくして得られる中間体(B)、すなわち(3S,4
S)−3−メトキシ−4−メチルアミノピロリジンまた
はその酸付加塩は、その3位のアミノ基が保護されてい
ないにももかかわらず、その1位において、ピリドンカ
ルボン酸の7位と結合することができる。
Production method (IV): Production of final product (C)
The intermediate (B) thus obtained, ie (3S, 4
S) -3-methoxy-4-methylaminopyrrolidine or an acid addition salt thereof binds at the 1-position to the 7-position of the pyridonecarboxylic acid even though the amino group at the 3-position is not protected. be able to.

【0051】すなわち、本発明は、次の工程10および
11を順次行うことを特徴とする次式(C)
That is, the present invention is characterized in that the following steps 10 and 11 are sequentially performed.

【0052】[0052]

【化24】 Embedded image

【0053】で表される(+)−1,4−ジヒドロ−7
−〔(3S,4S)−3−メトキシ−4−メチルアミノ
−1−ピロリジニル〕−4−オキソ−1−(2−チアゾ
リル)−1,8−ナフチリジン−3−カルボン酸または
その生理的に許容される塩の製造方法に関するものであ
る。
(+)-1,4-dihydro-7 represented by
-[(3S, 4S) -3-methoxy-4-methylamino-1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid or a physiologically acceptable salt thereof And a method for producing a salt.

【0054】〔工程10〕:本工程は、製造方法(III)
により製造された(3S,4S)−3−メトキシ−4−
メチルアミノピロリジン(B)またはその酸付加塩と次
式(7)
[Step 10]: This step is performed according to the production method (III).
(3S, 4S) -3-methoxy-4- produced by
Methylaminopyrrolidine (B) or an acid addition salt thereof and the following formula (7)

【0055】[0055]

【化25】 Embedded image

【0056】(式中、Lは脱離基を意味し、Rは水素原
子または低級アルキル基を意味する)で表される化合物
またはその塩とを反応させることから構成される。本工
程10で得た化合物は、精製して、または精製すること
なく次の工程11の原料として用いられる。
(Wherein, L represents a leaving group and R represents a hydrogen atom or a lower alkyl group) or a salt thereof. The compound obtained in this step 10 is used as a starting material for the next step 11 with or without purification.

【0057】〔工程11〕:本工程は前工程10で得た
化合物が低級アルキルエステルであるときはこれを加水
分解し、遊離体が得られたときは所望によりこれを生理
的に許容される塩に変換し、塩が得られたときは所望に
よりこれを遊離体に変換することから構成される。
[Step 11]: In this step, when the compound obtained in the preceding step 10 is a lower alkyl ester, it is hydrolyzed, and when a free form is obtained, it is optionally physiologically acceptable. It consists of converting to a salt and, if desired, converting it to the free form when a salt is obtained.

【0058】[0058]

【実施例】次に実施例を挙げて本発明をさらに詳細に説
明する。
Next, the present invention will be described in more detail with reference to examples.

【0059】製造方法(I):中間体(A)の製造−− 〔工程1〕:1 −tert−ブトキシカルボニル−3 −ピロ
リンの製造−−水素化ナトリウム(60%鉱油中) 4.20g
をn−ヘキサン40mlで洗浄して鉱油を除き、無水ジメチ
ルホルムアミド60mLを加え、懸濁液とした。この懸濁液
にシス−1,4 −ジクロロ−2 −ブテン(純度95%) 8.2
8gを加えた後、無水ジメチルホルムアミド60mlに溶解し
たtert−ブチルカルバメイト5gを滴下した。室温にて
40分撹拌後、65℃で5時間撹拌した。飽和塩化アンモニ
ウム水にて中和し、酢酸エチルにて 3回抽出した。飽和
食塩水にて4回洗浄し無水硫酸ナトリウムで乾燥後、減
圧下で溶媒を留去し、1−tert−ブトキシカルボニル−
3−ピロリンと酢酸エチルとの混合物7.5gを油状物とし
て得た。1H-NMRの結果から収率55%と算出された。
Production method (I): Production of intermediate (A) -[Step 1]: Production of 1-tert-butoxycarbonyl-3-pyrroline--Sodium hydride (60% in mineral oil) 4.20 g
Was washed with 40 ml of n-hexane to remove mineral oil, and 60 ml of anhydrous dimethylformamide was added to form a suspension. Add cis-1,4-dichloro-2-butene (purity 95%) to this suspension 8.2.
After adding 8 g, 5 g of tert-butyl carbamate dissolved in 60 ml of anhydrous dimethylformamide was added dropwise. At room temperature
After stirring for 40 minutes, the mixture was stirred at 65 ° C for 5 hours. The mixture was neutralized with a saturated aqueous solution of ammonium chloride and extracted three times with ethyl acetate. After washing with saturated saline four times and drying over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure to give 1-tert-butoxycarbonyl-
7.5 g of a mixture of 3-pyrroline and ethyl acetate was obtained as an oil. The yield was calculated to be 55% from the result of 1 H-NMR.

【0060】1H NMR (200MHz, CDCl3)δ: 1.48(s, 9
H), 4.06-4.19(m, 4H), 5.70-5.84(m, 2H)
1 H NMR (200 MHz, CDCl 3 ) δ: 1.48 (s, 9
H), 4.06-4.19 (m, 4H), 5.70-5.84 (m, 2H)

【0061】〔工程2〕:1−tert−ブトキシカルボニ
ル−トランス−3−ブロモ−4−ヒドロキシピロリジン
(2)の製造−−前工程で得られた化合物3.75g (酢酸
エチルを含む)をジメチルスルホキシド10mlおよび水0.
5ml に溶解し、氷冷下、1N−ブロモスクシンイミド2.
4gを少しずつ加えた。室温で1時間撹拌した後、酢酸エ
チルにて抽出し、飽和食塩水で洗浄した。無水硫酸マグ
ネシウムで乾燥後、減圧下で溶媒を留去し、1−tert−
ブトキシカルボニル−トランス−3−ブロモ−4−ヒド
ロキシピロリジン3.4gを油状物として得た。
[Step 2]: Production of 1-tert-butoxycarbonyl-trans-3-bromo-4-hydroxypyrrolidine (2)-3.75 g (including ethyl acetate) of the compound obtained in the previous step was treated with dimethyl sulfoxide. 10 ml and water 0.
Dissolve in 5 ml, and add 1N-bromosuccinimide under ice-cooling.
4 g was added little by little. After stirring at room temperature for 1 hour, the mixture was extracted with ethyl acetate and washed with saturated saline. After drying over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and 1-tert-
3.4 g of butoxycarbonyl-trans-3-bromo-4-hydroxypyrrolidine were obtained as an oil.

【0062】〔工程3〕:1−tert−ブトキシカルボニ
ル−トランス−3−ベンジルアミノ−4−ヒドロキシピ
ロリジン(A)の製造−−前工程で得られた粗生成物に
1N−水酸化ナトリウム水溶液14mlを加え、室温で1時
間撹拌した。次いでベンジルアミン3.1gを加え、65℃で
一夜撹拌した。反応液を氷冷後、析出結晶を濾取し、ア
セトニトリルで洗浄して中間体(A)、すなわち1−te
rt−ブトキシカルボニル−トランス−3−ベンジルアミ
ノ−4−ヒドロキシピロリジン1.6g(工程2からの収率
49%)を得た。
[Step 3]: Production of 1-tert-butoxycarbonyl-trans-3-benzylamino-4-hydroxypyrrolidine (A)-The crude product obtained in the preceding step was added to the crude product obtained in the previous step in 14 ml of a 1N aqueous sodium hydroxide solution. Was added and stirred at room temperature for 1 hour. Next, 3.1 g of benzylamine was added, and the mixture was stirred at 65 ° C. overnight. After cooling the reaction solution on ice, the precipitated crystals were collected by filtration, washed with acetonitrile, and washed with intermediate (A), ie, 1-te
1.6 g of rt-butoxycarbonyl-trans-3-benzylamino-4-hydroxypyrrolidine (yield from step 2)
49%).

【0063】融点:141 −143 ℃。 IR(KBr) :3250, 1670, 1605 cm -11 H NMR (200MHz, CDCl3)δ: 1.46(s, 9H), 3.10-3.35
(m, 3H), 3.57-3.75(m, 2H), 3.82(d, 2H, J=5.0Hz),
4.06-4.15(m, 1H),7.21-7.38(m, 5H)
Melting point: 141-143 ° C. IR (KBr): 3250, 1670, 1605 cm -1 . 1 H NMR (200 MHz, CDCl 3 ) δ: 1.46 (s, 9H), 3.10-3.35
(m, 3H), 3.57-3.75 (m, 2H), 3.82 (d, 2H, J = 5.0Hz),
4.06-4.15 (m, 1H), 7.21-7.38 (m, 5H)

【0064】製造方法(II):中間体(A)の製造−−
工程4および5を連続して行った。すなわち、3−ピロ
リン(純度 93.9 %)399gをクロロホルム5800mlに溶解
し、氷冷攪拌下、二炭酸ジtert−ブチル1.32kgを1.5 時
間かけて加えた。温度を室温まで上げ、さらに17時間撹
拌した後、氷冷下、m−クロロ過安息香酸(純度 75
%) 1.46kg を6時間かけて加えた。温度を室温まで上
げ2日間撹拌し、析出物を濾過し、濾液に飽和チオ硫酸
ナトリウム水溶液1000mlを加えて30分撹拌した。有機層
を分液し、5%炭酸カリウム水溶液5000mlにて2回、更
に飽和食塩水3000mlにて洗浄後、減圧下で溶媒を留去し
た。室温にて残渣に水1540mlおよびベンジルアミン1540
mlを加えた。反応液を2時間撹拌した後、65℃にて3時
間撹拌した。反応液に水2000mlおよび酢酸エチル9000ml
を加え撹拌後、有機層を分液し、水2500mlにて2回洗浄
し、減圧下で溶媒を留去した。残渣にジイソプロピルエ
ーテル6000mlを加えて析出する1−tert−ブトキシカル
ボニル−トランス−3−ベンジルアミノ−4−ヒドロキ
シピロリジン(収率42%)を得た。
Production method (II): Production of intermediate (A)
Steps 4 and 5 were performed sequentially. That is, 399 g of 3-pyrroline (purity: 93.9%) was dissolved in 5800 ml of chloroform, and 1.32 kg of di-tert-butyl dicarbonate was added over 1.5 hours while stirring with ice cooling. After raising the temperature to room temperature and stirring for further 17 hours, m-chloroperbenzoic acid (purity 75
%) 1.46 kg was added over 6 hours. The temperature was raised to room temperature, and the mixture was stirred for 2 days. The precipitate was filtered, 1000 ml of a saturated aqueous solution of sodium thiosulfate was added to the filtrate, and the mixture was stirred for 30 minutes. The organic layer was separated, washed twice with 5% aqueous potassium carbonate solution (5000 ml) and further with saturated saline (3000 ml), and the solvent was distilled off under reduced pressure. At room temperature, 1540 ml of water and benzylamine 1540 were added to the residue.
ml was added. After stirring the reaction solution for 2 hours, it was stirred at 65 ° C. for 3 hours. 2000 ml of water and 9000 ml of ethyl acetate are added to the reaction solution.
Was added, and the mixture was stirred. The organic layer was separated, washed twice with 2500 ml of water, and the solvent was distilled off under reduced pressure. Diisopropyl ether (6000 ml) was added to the residue to obtain 1-tert-butoxycarbonyl-trans-3-benzylamino-4-hydroxypyrrolidine (42% yield).

【0065】融点: 140−141 ℃。 IR(KBr) :3250, 1670, 1605 cm -11 H NMR (200MHz, CDCl3)δ: 1.46(s, 9H), 3.10-3.35
(m, 3H), 3.57-3.75(m, 2H), 3.82(d, 2H, J=5.0Hz),
4.06-4.15(m, 1H), 7.21-7.38(m, 5H)
Melting point: 140-141 ° C. IR (KBr): 3250, 1670, 1605 cm -1 . 1 H NMR (200 MHz, CDCl 3 ) δ: 1.46 (s, 9H), 3.10-3.35
(m, 3H), 3.57-3.75 (m, 2H), 3.82 (d, 2H, J = 5.0Hz),
4.06-4.15 (m, 1H), 7.21-7.38 (m, 5H)

【0066】製造方法(III) :中間体(B)の製造−−
〔工程6−1〕:(+)−1−tert−ブトキシカルボニ
ル−(3S ,4S) −3−ベンジルアミノ−4−ヒドロキシ
ピロリジンのマンデル酸塩の製造−−製造方法(I)ま
たは(II)のいずれかにおいて製造された1−tert−ブ
トキシカルボニル−トランス−3−ベンジルアミノ−4
−ヒドロキシ−3−ピロリジン(A)714gおよび(+)
−マンデル酸 411g をアセトニトリル7500mlと水 62ml
の混液に溶解し、室温で3.5 時間放置した。析出した結
晶を濾取し、アセトニトリルと水の混液(20:1、V/V
)から3回再結晶して(+)−1−tert−ブトキシカ
ルボニル−(3S ,4S) −3−ベンジルアミノ−4−ヒド
ロキシピロリジンのマンデル酸塩を得た。
Production method (III): Production of intermediate (B)
[Step 6-1]: Production of mandelic acid salt of (+)-1-tert-butoxycarbonyl- (3S, 4S) -3-benzylamino-4-hydroxypyrrolidine--Production method (I) or (II) 1-tert-butoxycarbonyl-trans-3-benzylamino-4 produced in any of the above
714 g of -hydroxy-3-pyrrolidine (A) and (+)
-411 g of mandelic acid in 7500 ml of acetonitrile and 62 ml of water
And left at room temperature for 3.5 hours. The precipitated crystals are collected by filtration and mixed with acetonitrile and water (20: 1, V / V
) Was recrystallized three times to obtain the mandelic acid salt of (+)-1-tert-butoxycarbonyl- (3S, 4S) -3-benzylamino-4-hydroxypyrrolidine.

【0067】融点:189 −191 ℃。1 H NMR(200MHz, DMSO-d6) δ: 1.39(s, 9H), 2.91-3.1
8(m, 3H), 3.22-3.50(m,4H), 3.72(s, 1H), 3.95-4.02
(m, 1H), 4.98(s, 1H), 4.98-5.18(m, 1H), 7.19-7.44
(m, 10H)
Melting point: 189-191 ° C. 1 H NMR (200 MHz, DMSO-d 6 ) δ: 1.39 (s, 9H), 2.91-3.1
8 (m, 3H), 3.22-3.50 (m, 4H), 3.72 (s, 1H), 3.95-4.02
(m, 1H), 4.98 (s, 1H), 4.98-5.18 (m, 1H), 7.19-7.44
(m, 10H)

【0068】〔工程6−2〕:(+)−1−tert−ブト
キシカルボニル−(3S ,4S) −3−ベンジルアミノ−4
−ヒドロキシピロリジンの製造−−前工程で得た化合物
に9%炭酸カリウム水溶液3000mlを加えてアルカリ性と
なし、酢酸エチル(合わせて7000ml) にて3回抽出し
た。飽和食塩水1500mlにて洗浄し無水硫酸ナトリウムで
乾燥後、減圧下で溶媒を留去した。残渣にジイソプロピ
ルエーテル1700mlを加えて結晶化させ、結晶を濾取して
(+)−1−tert−ブトキシカルボニル−(3S,4 S
) −3−ベンジルアミノ−4−ヒドロキシピロリジン2
74g(工程6−1からの収率77%)を得た。
[Step 6-2]: (+)-1-tert-butoxycarbonyl- (3S, 4S) -3-benzylamino-4
-Production of hydroxypyrrolidine- The compound obtained in the preceding step was made alkaline by adding 3000 ml of a 9% aqueous potassium carbonate solution, and extracted three times with ethyl acetate (7000 ml in total). After washing with saturated saline (1500 ml) and drying over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure. The residue was crystallized by adding 1700 ml of diisopropyl ether, and the crystals were collected by filtration to give (+)-1-tert-butoxycarbonyl- (3S, 4S
) -3-Benzylamino-4-hydroxypyrrolidine 2
74 g (77% yield from step 6-1) were obtained.

【0069】融点: 69 −70℃。 〔α〕D 29= +18.0°(c= 0.50, MeOH)。 IR(KBr) : 3250, 1670, 1605 cm-11 H NMR (200MHz,CDCl3) δ:1.46(s, 9H), 3.10-3.35
(m, 3H), 3.57-3.75(m, 2H), 3.82(d, 2H, J=5.0Hz),
4.06-4.15(m, 1H), 7.21-7.38(m, 5H)
Melting point: 69-70 ° C. [Α] D 29 = + 18.0 ° (c = 0.50, MeOH). IR (KBr): 3250, 1670, 1605 cm -1 . 1 H NMR (200 MHz, CDCl 3 ) δ: 1.46 (s, 9H), 3.10-3.35
(m, 3H), 3.57-3.75 (m, 2H), 3.82 (d, 2H, J = 5.0Hz),
4.06-4.15 (m, 1H), 7.21-7.38 (m, 5H)

【0070】〔工程7〕:(+)−1−tert−ブトキシ
カルボニル−(3S ,4S) −3−tert−ブトキシカルボニ
ルアミノ−4−ヒドロキシピロリジン(5)の製造−−
前工程で得た化合物274gをn−ブタノ−ル1200mlに溶解
し、5%パラジウム−炭素 13.7gを加え、15−50℃にて
水素添加した。触媒を吸引濾過し、濾液にエタノール 8
00mlを加えた後、氷冷下、二炭酸ジtert−ブチル 215g
を10分間かけて加えた。温度を室温まで上げ16時間撹拌
し、反応液を減圧下乾固した。残渣にジイソプロピルエ
ーテル1800mlを加えて結晶化させ、結晶を濾取して
(+)−1−tert−ブトキシカルボニル−(3S ,4S) −
3−tert−ブトキシカルボニルアミノ−4−ヒドロキシ
ピロリジン278g(収率98%)を得た。
[Step 7] Production of (+)-1-tert-butoxycarbonyl- (3S, 4S) -3-tert-butoxycarbonylamino-4-hydroxypyrrolidine (5)
274 g of the compound obtained in the preceding step was dissolved in 1200 ml of n-butanol, 13.7 g of 5% palladium-carbon was added, and hydrogenated at 15-50 ° C. The catalyst was filtered off with suction, and ethanol 8 was added to the filtrate.
After adding 00 ml, under ice cooling, ditert-butyl dicarbonate 215 g
Was added over 10 minutes. The temperature was raised to room temperature and stirred for 16 hours, and the reaction solution was evaporated to dryness under reduced pressure. The residue was crystallized by adding 1800 ml of diisopropyl ether, and the crystals were collected by filtration to give (+)-1-tert-butoxycarbonyl- (3S, 4S)-
278 g (98% yield) of 3-tert-butoxycarbonylamino-4-hydroxypyrrolidine were obtained.

【0071】融点: 148− 149℃。 〔α〕D 29= +1.80°(c= 1.00, MeOH ) 。 IR(KBr) :3470, 3300, 1670 cm -11 H NMR (200MHz,CDCl3 )δ: 1.45(s, 9H), 1.46(s, 9
H), 3.10-3.38(m, 2H), 3.61-4.01(m, 3H), 4.16-4.29
(m, 1H), 4.59-4.85(m, 1H)
Melting point: 148-149 ° C. [Α] D 29 = + 1.80 ° (c = 1.00, MeOH). IR (KBr): 3470, 3300, 1670 cm -1 . 1 H NMR (200 MHz, CDCl 3 ) δ: 1.45 (s, 9H), 1.46 (s, 9
H), 3.10-3.38 (m, 2H), 3.61-4.01 (m, 3H), 4.16-4.29
(m, 1H), 4.59-4.85 (m, 1H)

【0072】〔工程8〕:(+)−1−tert−ブトキシ
カルボニル−(3S ,4S) −3−〔(N−tert−ブトキシ
カルボニル−N−メチル)アミノ〕−4−メトキシピロ
リジン(6)の製造−−水素化ナトリウム(60%鉱油
中) 66.4gをn−ヘキサン700 mlで2回洗浄して鉱油を
除き、ついで無水ジメチルホルムアミド1400mlを加え懸
濁液とした。この懸濁液に氷冷にてヨウ化メチル283gを
加えた後、工程7で得た化合物200gを溶解した無水ジメ
チルホルムアミド1000mlを1時間かけて滴下した。温度
を室温まで上げ19時間撹拌し、2%酢酸水溶液2700mlに
て中和し、トルエン(合わせて4500ml)にて3回抽出し
た。飽和食塩水1000mlにて3回洗浄後、無水硫酸ナトリ
ウムで乾燥した。減圧下で溶媒を留去し、(+)−1−
tert−ブトキシカルボニル−(3S ,4S) −3−tert−
〔(N−ブトキシカルボニル−N−メチル)アミノ〕−
4−メトキシピロリジン218gを無色油状物として定量的
に得た。
[Step 8]: (+)-1-tert-butoxycarbonyl- (3S, 4S) -3-[(N-tert-butoxycarbonyl-N-methyl) amino] -4-methoxypyrrolidine (6) Preparation of 66.4 g of sodium hydride (in 60% mineral oil) was washed twice with 700 ml of n-hexane to remove the mineral oil, and then 1400 ml of anhydrous dimethylformamide was added to form a suspension. After adding 283 g of methyl iodide to the suspension under ice cooling, 1000 ml of anhydrous dimethylformamide in which 200 g of the compound obtained in the step 7 was dissolved was added dropwise over 1 hour. The temperature was raised to room temperature, stirred for 19 hours, neutralized with 2700 ml of a 2% acetic acid aqueous solution, and extracted three times with toluene (4500 ml in total). After washing three times with 1000 ml of a saturated saline solution, the resultant was dried with anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and (+)-1-
tert-butoxycarbonyl- (3S, 4S) -3-tert-
[(N-butoxycarbonyl-N-methyl) amino]-
218 g of 4-methoxypyrrolidine was obtained quantitatively as a colorless oil.

【0073】〔α〕D 29= +9.03°(c= 0.55, MeOH
)。 IR(NaCl): 2980, 1690 cm-11 H NMR(200MHz, CDCl3) δ: 1.47(s, 9H), 1.48(s, 9
H), 2.79(s, 3H), 3.21-3.39(m, 2H), 3.39(s, 3H), 3.
53-3.74(m, 2H), 3.80-3.89(m, 1H), 4.40-4.52(m, 1H)
[Α] D 29 = + 9.03 ° (c = 0.55, MeOH
). IR (NaCl): 2980, 1690 cm -1 . 1 H NMR (200 MHz, CDCl 3 ) δ: 1.47 (s, 9H), 1.48 (s, 9
H), 2.79 (s, 3H), 3.21-3.39 (m, 2H), 3.39 (s, 3H), 3.
53-3.74 (m, 2H), 3.80-3.89 (m, 1H), 4.40-4.52 (m, 1H)

【0074】〔工程9〕:(3S ,4S) −3−メトキシ−
4−メチルアミノピロリジン(B)の二p−トルエンス
ルホン酸塩の製造−−前工程で得た化合物218gをテトラ
ヒドロフラン−メタノール(3:1,V/V )混液3300ml
に溶解し、p−トルエンスルホン酸一水和物289gを加え
た。30分間撹拌後、60℃で3時間撹拌し、室温にて放置
した。氷冷後、析出結晶を濾取し、(+)−(3S,4
S)−3−メトキシ−4−メチルアミノピロリジン二p
−トルエンスルホン酸286g(収率91%)を得た。
[Step 9]: (3S, 4S) -3-methoxy-
Preparation of di-p-toluenesulfonate of 4-methylaminopyrrolidine (B)-3,200 ml of a mixture of 218 g of the compound obtained in the preceding step and tetrahydrofuran-methanol (3: 1, V / V)
And 289 g of p-toluenesulfonic acid monohydrate was added. After stirring for 30 minutes, the mixture was stirred at 60 ° C. for 3 hours and left at room temperature. After cooling on ice, the precipitated crystals were collected by filtration and (+)-(3S, 4
S) -3-Methoxy-4-methylaminopyrrolidine di-p
-286 g of toluenesulfonic acid (91% yield) were obtained.

【0075】融点:163 − 164℃。 〔α〕D 29= +10.4°(c= 1.05, MeOH )。 IR(KBr) : 3060, 1617, 1570 cm-11 H NMR (200MHz,DMSO-d6) δ: 2.70(s, 3H), 3.22-3.4
8(m, 3H), 3.32(s, 3H),3.60-4.71(m, 1H), 3.79-3.90
(m, 1H), 4.19-4.26(m, 1H)
Melting point: 163-164 ° C. [Α] D 29 = + 10.4 ° (c = 1.05, MeOH). IR (KBr): 3060, 1617, 1570 cm -1 . 1 H NMR (200 MHz, DMSO-d 6 ) δ: 2.70 (s, 3H), 3.22-3.4
8 (m, 3H), 3.32 (s, 3H), 3.60-4.71 (m, 1H), 3.79-3.90
(m, 1H), 4.19-4.26 (m, 1H)

【0076】製造方法(IV):最終目的物(C)の製造
−− 〔工程10〕:7位置換反応−−工程9で得た(+)−
(3S,4S)−3−メトキシ−4−メチルアミノピロ
リジン二p−トルエンスルホン酸95.3g をアセトニトリ
ル600ml に懸濁させ、氷冷下、トリエチルアミン120ml
を加えた。15分間攪拌した後、7−クロロ−1,4−ジ
ヒドロ−4−オキソ−1−(2−チアゾリル)−1,8
−ナフチリジン−3−カルボン酸エチルエステル60.3g
を加えた。室温で1時間攪拌した後、アセトニトリル15
0ml を加え、同温度にて1日間攪拌した。析出結晶を濾
取し、アセトニトリルで洗浄して(−)−1,4−ジヒ
ドロ−7−〔(3S,4S)−3−メトキシ−4−メチ
ルアミノ−1−ピロリジニル〕−4−オキソ−1−(2
−チアゾリル)−1,8−ナフチリジン−3−カルボン
酸エチルエステルを得た。
Production method (IV): Production of final target product (C) [Step 10]: 7-substitution reaction-(+) obtained in Step 9
95.3 g of (3S, 4S) -3-methoxy-4-methylaminopyrrolidine dip-toluenesulfonic acid was suspended in 600 ml of acetonitrile, and 120 ml of triethylamine was suspended under ice-cooling.
Was added. After stirring for 15 minutes, 7-chloro-1,4-dihydro-4-oxo-1- (2-thiazolyl) -1,8
-Naphthyridine-3-carboxylic acid ethyl ester 60.3 g
Was added. After stirring for 1 hour at room temperature, acetonitrile 15
0 ml was added and the mixture was stirred at the same temperature for 1 day. The precipitated crystals are collected by filtration, washed with acetonitrile, and washed with (-)-1,4-dihydro-7-[(3S, 4S) -3-methoxy-4-methylamino-1-pyrrolidinyl] -4-oxo-1. -(2
-Thiazolyl) -1,8-naphthyridine-3-carboxylic acid ethyl ester was obtained.

【0077】融点:184−185℃。 〔α〕D 28= -16.9°(c= 0.50, クロロホルム)Melting point: 184-185 ° C. [Α] D 28 = -16.9 ° (c = 0.50, chloroform)

【0078】〔工程11〕:最終目的物の製造−−前工
程で得たエステルに0.5N水酸化ナトリウム水溶液430ml
とエタノール12mlを加え、室温で2日間攪拌した。反応
液に28%アンモニア水21mlと50%酢酸水34.5mlを加え、
80℃で2時間攪拌した。氷冷後、析出結晶を濾取し、水
およびエタノールで順次洗浄して(+)−1,4−ジヒ
ドロ−7−〔(3S,4S)−3−メトキシ−4−メチ
ルアミノ−1−ピロリジニル〕−4−オキソ−1−(2
−チアゾリル)−1,8−ナフチリジン−3−カルボン
酸64.8g(工程10からの収率90%)を得た。
[Step 11]: Preparation of final target-430 ml of 0.5N sodium hydroxide aqueous solution was added to the ester obtained in the previous step.
And ethanol (12 ml), and the mixture was stirred at room temperature for 2 days. 21 ml of 28% aqueous ammonia and 34.5 ml of 50% aqueous acetic acid were added to the reaction solution,
Stirred at 80 ° C. for 2 hours. After cooling on ice, the precipitated crystals are collected by filtration, washed successively with water and ethanol, and washed with (+)-1,4-dihydro-7-[(3S, 4S) -3-methoxy-4-methylamino-1-pyrrolidinyl. ] -4-oxo-1- (2
-Thiazolyl) -1,8-naphthyridine-3-carboxylic acid (64.8 g, 90% yield from step 10) was obtained.

【0079】融点:278 −280 ℃(分解)。 〔α〕D 29= +58.5°(c=1.00, 1N NaOH)Melting point: 278-280 ° C. (decomposition). [Α] D 29 = + 58.5 ° (c = 1.00, 1N NaOH)

【0080】[0080]

【発明の効果】本発明方法は、工業的製法として従来法
よりもはるかに優れている。
The method of the present invention is far superior to the conventional method as an industrial production method.

Claims (5)

【特許請求の範囲】[Claims] 【請求項1】 次式(A) 【化1】 (式中、Bocはtert−ブトキシカルボニル基を意味
し、Phはフェニル基を意味する)で表される1−tert
−ブトキシカルボニル−トランス−3−ベンジルアミノ
−4−ヒドロキシピロリジンまたはその酸付加塩。
(1) The following formula (A): (Wherein Boc means a tert-butoxycarbonyl group, and Ph means a phenyl group)
-Butoxycarbonyl-trans-3-benzylamino-4-hydroxypyrrolidine or an acid addition salt thereof.
【請求項2】 次の工程1−3を順次行うことを特徴と
する1−tert−ブトキシカルボニル−トランス−3−ベ
ンジルアミノ−4−ヒドロキシピロリジン(A)の製造
方法: 〔工程1〕:水素化ナトリウムの存在下、次式(1) 【化2】 で表されるシス−1,4−ジクロロ−2−ブテンにtert
−ブチルカルバメイトを反応させて1−tert−ブトキシ
カルボニル−3−ピロリンとなす工程、 〔工程2〕:工程1で得られた化合物にN−ブロモスク
シンイミドを反応させて次式(2) 【化3】 (式中、Bocはtert−ブトキシカルボニル基を意味す
る)で表される1−tert−ブトキシカルボニル−トラン
ス−3−ブロモ−4−ヒドロキシピロリジンとなす工
程、 〔工程3〕:工程2で得た化合物に塩基、次いでベンジ
ルアミンを反応させて1−tert−ブトキシカルボニル−
トランス−3−ベンジルアミノ−4−ヒドロキシピロリ
ジン(A)となす工程。
2. A process for producing 1-tert-butoxycarbonyl-trans-3-benzylamino-4-hydroxypyrrolidine (A), which comprises sequentially performing the following steps 1-3: [Step 1]: hydrogen In the presence of sodium chloride, the following formula (1) Tert-1,4-dichloro-2-butene represented by tert
Step of reacting 1-tert-butoxycarbonyl-3-pyrroline by reacting -butylcarbamate [Step 2]: reacting the compound obtained in Step 1 with N-bromosuccinimide to obtain the following formula (2) 3] (In the formula, Boc means a tert-butoxycarbonyl group) 1-tert-butoxycarbonyl-trans-3-bromo-4-hydroxypyrrolidine represented by the following formula: [Step 3]: obtained in Step 2 The compound is reacted with a base and then with benzylamine to give 1-tert-butoxycarbonyl-
Step of forming trans-3-benzylamino-4-hydroxypyrrolidine (A).
【請求項3】 次の工程4および5を順次行うことを特
徴とする1−tert−ブトキシカルボニル−トランス−3
−ベンジルアミノ−4−ヒドロキシピロリジン(A)の
製造方法: 〔工程4〕:次式(3) 【化4】 で表される3−ピロリンの1位にtert−ブトキシカルボ
ニル基(本項において以下Boc基という)を導入して
1−tert−ブトキシカルボニル−3−ピロリンとなす工
程、 〔工程5〕:工程4で得られた化合物を酸化して次式
(4) 【化5】 で表される化合物となし、これにベンジルアミンを反応
させて1−tert−ブトキシカルボニル−トランス−3−
ベンジルアミノ−4−ヒドロキシピロリジン(A)とな
す工程。
3. The following steps 4 and 5 are sequentially performed: 1-tert-butoxycarbonyl-trans-3
Method for producing -benzylamino-4-hydroxypyrrolidine (A): [Step 4]: The following formula (3): A step of introducing a tert-butoxycarbonyl group (hereinafter referred to as a Boc group in this section) at the 1-position of 3-pyrroline represented by the formula (1) to form 1-tert-butoxycarbonyl-3-pyrroline; [Step 5]: Step 4 The compound obtained in the above is oxidized to give the following formula (4): And reacted with benzylamine to give 1-tert-butoxycarbonyl-trans-3-
A step of forming benzylamino-4-hydroxypyrrolidine (A).
【請求項4】 以下の工程6−9を順次行うことを特徴
とする次式(B) 【化6】 で表される(3S,4S)−3−メトキシ−4−メチル
アミノピロリジンまたはその酸付加塩の製造方法: 〔工程6〕:次式(A) 【化7】 (式中、Bocはtert−ブトキシカルボニル基を意味
し、Phはフェニル基を意味する。本項において以下同
様。)で表される1−tert−ブトキシカルボニル−トラ
ンス−3−ベンジルアミノ−4−ヒドロキシピロリジン
(A)を(+)−マンデル酸により光学分割を行った
後、塩基処理して遊離の(+)−1−tert−ブトキシカ
ルボニル−(3S,4S)−3−ベンジルアミノ−4−
ヒドロキシピロリジンとなす工程、 〔工程7〕:工程6で得た化合物を脱ベンジル化反応お
よびBoc基導入反応に付して次式(5) 【化8】 で表される(+)−1−tert−ブトキシカルボニル−
(3S,4S)−3−tert−ブトキシカルボニルアミノ
−4−ヒドロキシピロリジンとなす工程、 〔工程8〕:水素化ナトリウムの存在下、工程7で得た
化合物をメチル化して次式(6) 【化9】 で表される(+)−1−tert−ブトキシカルボニル−
(3S,4S)−3−〔N−tert−ブトキシカルボニル
−N−メチル)アミノ〕−4−メトキシピロリジンとな
す工程、 〔工程9〕:工程8で得られた化合物のBoc基を脱離
して目的化合物(B)となし、次いで所望により、遊離
塩基が得られたときは酸付加塩に変換し、酸付加塩が得
られたときは遊離塩基に変換する工程。
4. The following step (6) is performed sequentially: Method for producing (3S, 4S) -3-methoxy-4-methylaminopyrrolidine or an acid addition salt thereof represented by the following formula: [Step 6]: Formula (A): (In the formula, Boc means a tert-butoxycarbonyl group, and Ph means a phenyl group; the same applies hereinafter in this section.) 1-tert-butoxycarbonyl-trans-3-benzylamino-4- The hydroxypyrrolidine (A) is subjected to optical resolution with (+)-mandelic acid, and then treated with a base to give free (+)-1-tert-butoxycarbonyl- (3S, 4S) -3-benzylamino-4-.
[Step 7]: subjecting the compound obtained in step 6 to a debenzylation reaction and a Boc group introduction reaction to give the following formula (5): (+)-1-tert-butoxycarbonyl- represented by
(3S, 4S) -3-tert-butoxycarbonylamino-4-hydroxypyrrolidine [Step 8]: The compound obtained in Step 7 is methylated in the presence of sodium hydride to give the following formula (6) 9 (+)-1-tert-butoxycarbonyl- represented by
(3S, 4S) -3- [N-tert-butoxycarbonyl-N-methyl) amino] -4-methoxypyrrolidine [Step 9]: removing the Boc group of the compound obtained in Step 8 Converting the compound to an acid addition salt when a free base is obtained, and then converting it to a free base when an acid addition salt is obtained, if desired.
【請求項5】 次の工程10および11を順次行うこと
を特徴とする次式(C) 【化10】 で表される(+)−1,4−ジヒドロ−7−〔(3S,
4S)−3−メトキシ−4−メチルアミノ−1−ピロリ
ジニル〕−4−オキソ−1−(2−チアゾリル)−1,
8−ナフチリジン−3−カルボン酸またはその生理的に
許容される塩の製造方法: 〔工程10〕:請求項4に記載の方法により製造された
(3S,4S)−3−メトキシ−4−メチルアミノピロ
リジン(B)またはその酸付加塩と次式(7) 【化11】 (式中、Lは脱離基を意味し、Rは水素原子または低級
アルキル基を意味する)で表される化合物またはその塩
とを反応させる工程、 〔工程11〕工程10で得た化合物が低級アルキルエス
テルであるときはこれを加水分解し、遊離体が得られた
ときは所望によりこれを生理的に許容される塩に変換
し、塩が得られたときは所望によりこれを遊離体に変換
する工程。
5. The following formula (C) characterized by sequentially performing the following steps 10 and 11: (+)-1,4-dihydro-7-[(3S,
4S) -3-Methoxy-4-methylamino-1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,
Method for producing 8-naphthyridine-3-carboxylic acid or a physiologically acceptable salt thereof [Step 10]: (3S, 4S) -3-methoxy-4-methyl produced by the method according to claim 4. Aminopyrrolidine (B) or an acid addition salt thereof and the following formula (7): (Wherein L represents a leaving group, R represents a hydrogen atom or a lower alkyl group) or a salt thereof, [Step 11] wherein the compound obtained in Step 10 is When it is a lower alkyl ester, it is hydrolyzed, and when a free form is obtained, it is optionally converted to a physiologically acceptable salt, and when a salt is obtained, it is converted to a free form as desired. The process of converting.
JP17398698A 1998-06-05 1998-06-05 Process for producing pyridonecarboxylic acid derivatives and intermediates thereof Expired - Lifetime JP4294121B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP17398698A JP4294121B2 (en) 1998-06-05 1998-06-05 Process for producing pyridonecarboxylic acid derivatives and intermediates thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP17398698A JP4294121B2 (en) 1998-06-05 1998-06-05 Process for producing pyridonecarboxylic acid derivatives and intermediates thereof

Publications (2)

Publication Number Publication Date
JPH11349565A true JPH11349565A (en) 1999-12-21
JP4294121B2 JP4294121B2 (en) 2009-07-08

Family

ID=15970672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP17398698A Expired - Lifetime JP4294121B2 (en) 1998-06-05 1998-06-05 Process for producing pyridonecarboxylic acid derivatives and intermediates thereof

Country Status (1)

Country Link
JP (1) JP4294121B2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001072659A (en) * 1998-11-30 2001-03-21 Toray Ind Inc Production of pyrrolidine derivative
US7829577B2 (en) 2004-03-15 2010-11-09 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical compositions of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
US8124773B2 (en) 2006-06-12 2012-02-28 Sunesis Pharmaceuticals, Inc. 1,8-naphthyridine compounds for the treatment of cancer
JP2013503899A (en) * 2009-09-04 2013-02-04 サネシス ファーマシューティカルズ, インコーポレイテッド Stable SNS-595 composition and production method
US8470817B2 (en) 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
US8497282B2 (en) 2008-12-31 2013-07-30 Sunesis Pharmaceuticals, Inc. Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
US8518872B2 (en) 2007-10-22 2013-08-27 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
US8580814B2 (en) 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001072659A (en) * 1998-11-30 2001-03-21 Toray Ind Inc Production of pyrrolidine derivative
US7829577B2 (en) 2004-03-15 2010-11-09 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical compositions of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
US7968565B2 (en) 2004-03-15 2011-06-28 Sunesis Pharmaceuticals, Inc. Therapeutic combinations comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
US7989468B2 (en) 2004-03-15 2011-08-02 Sunesis Pharmaceuticals, Inc. Methods of using SNS-595
US9757363B2 (en) 2004-03-15 2017-09-12 Sunesis Pharmaceuticals, Inc. SNS-595 and methods of using the same
US9980949B2 (en) 2004-03-15 2018-05-29 Sunesis Pharmaceuticals, Inc. SNS-595 and methods of using the same
US8822493B2 (en) 2004-03-15 2014-09-02 Sunesis Pharmaceuticals, Inc. SNS-595 and methods of using the same
US8669270B2 (en) 2004-03-15 2014-03-11 Dainippon Sumitomo Pharma Co., Ltd. SNS-595 and methods of using the same
US8580814B2 (en) 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US8765954B2 (en) 2006-06-12 2014-07-01 Sunesis Pharmaceuticals, Inc. 1,8-naphthyridine compounds for the treatment of cancer
US9676774B2 (en) 2006-06-12 2017-06-13 Sunesis Pharmaceuticals, Inc. Compounds and compositions for treatment of cancer
US8124773B2 (en) 2006-06-12 2012-02-28 Sunesis Pharmaceuticals, Inc. 1,8-naphthyridine compounds for the treatment of cancer
US8518872B2 (en) 2007-10-22 2013-08-27 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
US9839630B2 (en) 2008-12-31 2017-12-12 Sunesis Pharmaceuticals, Inc. Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
US8802719B2 (en) 2008-12-31 2014-08-12 Sunesis Pharmaceuticals, Inc. Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
US8497282B2 (en) 2008-12-31 2013-07-30 Sunesis Pharmaceuticals, Inc. Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
JP2015180677A (en) * 2008-12-31 2015-10-15 サネシス ファーマシューティカルズ, インコーポレイテッド Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
JP2013503899A (en) * 2009-09-04 2013-02-04 サネシス ファーマシューティカルズ, インコーポレイテッド Stable SNS-595 composition and production method
US9469635B2 (en) 2009-09-04 2016-10-18 Sunesis Pharmaceuticals, Inc. Stable SNS-595 compositions and methods of preparation
US8586601B2 (en) 2009-09-04 2013-11-19 Sunesis Pharmaceuticals, Inc. Stable SNS-595 compositions and methods of preparation
US9969730B2 (en) 2009-09-04 2018-05-15 Sunesis Pharmaceuticals, Inc. Stable SNS-595 compositions and methods of preparation
JP2018127457A (en) * 2009-09-04 2018-08-16 サネシス ファーマシューティカルズ, インコーポレイテッド Stable sns-595 compositions and methods of preparation
US8470817B2 (en) 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer

Also Published As

Publication number Publication date
JP4294121B2 (en) 2009-07-08

Similar Documents

Publication Publication Date Title
ES2667054T3 (en) New substituted imidazoquinolines
EP2768806B1 (en) Method for preparing silodosin
EP1546149A1 (en) Modified pictet-spengler reaction and products prepared therefrom
EP1837336A1 (en) Preparation of valganciclovir
JP4294121B2 (en) Process for producing pyridonecarboxylic acid derivatives and intermediates thereof
JP3639449B2 (en) Method for producing 3-amino-pyrrolidine derivative
WO1998007687A1 (en) PROCESS FOR PREPARING β-AMINO-α-HYDROXY ACID DERIVATIVES
JP2018528233A (en) Process for producing indoline compounds and novel indoline salts
JP2010535185A (en) Method for producing alfuzosin hydrochloride
WO2014081047A1 (en) Process for the preparation of (1s,4s,5s)-4-bromo-6-oxabicyclo[3.2.1] octan-7-one
JP4368304B2 (en) Process for the preparation of amino-pyrrolidine derivatives
WO2000069817A1 (en) Process for producing optically active azetidine-2-carboxylic acids
WO2006090265A2 (en) Processes for the preparation of levetiracetam, its intermediate and the use of levetiracetam in pharmaceutical compositions
JP5130212B2 (en) Optically active 3-amino-2,5-dioxopyrrolidine-3-carboxylates, process for producing the same and use of the compounds
EP1590353B1 (en) A process for the preparation of cefpodoxime proxetil
JP4532801B2 (en) Method for preparing (-)-(1S, 4R) N protected 4-amino-2-cyclopentene-1-carboxylic acid ester
JP3518627B2 (en) Method for producing optically active 5-hydroxymethyloxazolidinone derivative
JPWO2004099136A1 (en) Method for producing pyrrolidine derivative
GB1566262A (en) 3 - amino - 4 - oxoazetidine derivatives
JPS59134796A (en) Preparation of 6-aminopenicillanic acid ester using tetraalkylammonium salt of 6-aminopenicillanic acid
JP3216673B2 (en) Method for producing 3-hydroxyisoxazole
JP2000026408A (en) Antipodally pure pyrrolidine derivative, its salt and their production
JP2921933B2 (en) Optically active butyric acid derivative
KR100566896B1 (en) Processes for the preparation of an optically active 5,6-dioxopiperazine-2-carboxylic acid derivative
KR19990024927A (en) Oxazolidinone derivatives, preparation method thereof and antimicrobial composition

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7421

Effective date: 20040506

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050530

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20081126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090331

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090408

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120417

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120417

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130417

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130417

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140417

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term